Oral lichen planus and the p53 family: What do we know?

Journal of Oral Pathology and Medicine

Volumn 40, Issue 4, 2011, Pages 281-285

  Ebrahimi, Majid ^a   Nylander, Karin ^a   van der Waal, Isaäc ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Oral lichen planus; P53 family; Potentially malignant oral disorder

Indexed keywords

PROTEIN P53; PROTEIN P63; PROTEIN P73; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; AUTOIMMUNITY; CARCINOGENESIS; CELL CYCLE ARREST; DNA DAMAGE; HUMAN; LICHEN PLANUS; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WORLD HEALTH ORGANIZATION;

APOPTOSIS; AUTOIMMUNITY; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENES, P53; HUMANS; LICHEN PLANUS, ORAL; MEMBRANE PROTEINS; MULTIGENE FAMILY; NUCLEAR PROTEINS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 79952851062     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00979.x     Document Type: Review

References (58)

1. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. WHO collaborating centre for oral precancerous lesions. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978; 46: 518-39.
2. van der Meij EH, Schepman KP, Plonait DR, Axéll T, van der Waal I. Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med 2002; 31: 95-8.
3. Sugerman PB, Savage NW, Walsh LJ, et al. Disease mechanisms in oral lichen planus. A possible role for autoimmunity. Australas J Dermatol 1993; 34: 63-9.
4. Sugerman PB, Savage NW. Oral lichen planus: causes, diagnosis and management. Austral Dent J 2002; 47: 290-7.
5. Lukac J, Brozovic S, Vucicevic-Boras V, Mravak-Stipetić M, Malenica B, Kusić Z. Serum autoantibodies to desmogleins 1 and 3 in patients with oral lichen planus. Croat Med J 2006; 47: 53-8.
6. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. In: World Health Organization international histological classification of tumours. Berlin: Springer, 1997, 30.
7. Eisenberg E. Oral lichen planus: a benign lesion. J Oral Maxillofac Surg 2000; 58: 1278-85.
8. van der Meij EH, Schepman KP, Smeele LE, van der Wal JE, Bezemer PD, van der Waal I. A review of the recent literature regarding malignant transformation of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 307-10.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
10. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671-4.
11. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14: 433-9.
12. Girod SC, Krueger G, Pape HD. p53 and Ki 67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int J Oral Maxillofac Surg 1993; 22: 285-8.
13. Montebugnoli L, Farnedi A, Marchetti C, Magrini E, Pession A, Foschini MP. High proliferative activity and chromosomal instability in oral lichen planus. Int J Oral Maxillofac Surg 2006; 35: 1140-4.
14. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40- transformed cells. Nature 1979; 278: 261-3.
15. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
16. Romer L, Klein C, Dehner A, Kessler H, Buchner J. p53 - a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl 2006; 45: 6440-60.
17. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-37.
18. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
19. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-19.
20. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissue and neoplastic cells. J Pathol 2002; 198: 417-27.
21. Thurfjell N, Coates PJ, Uusitalo T, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004; 25: 27-35.
22. Grob TJ, Novak U, Maisse C, et al. Human DNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 12: 1213-23.
23. Irwin MS, Kaelin WG. P53 family update: p73 and p63 develop their own identities. Cell Growth Diff 2001; 12: 337-49.
24. Chen YK, Hsue SS, Lin LM. p73 expression for human buccal epithelial dysplasia and squamous cell carcinoma: does it correlate with nodal status of carcinoma and is there a relationship with malignant change of epithelial dysplasia? Head Neck 2004; 26: 945-52.
25. Ebrahimi M, Wahlin YB, Coates PJ, Wiik A, Roos G, Nylander K. Detection of antibodies against p63 and p73 isoforms in sera from patients diagnosed with oral lichen planus. J Oral Pathol Med 2007; 36: 93-8.
26. Crosthwaite N, Teale D, Franklin C, Foster GA, Stringer BM. p53 protein expression in malignant, pre-malignant and non-malignant lesions of the lip. J Clin Pathol 1996; 49: 648-53.
27. Dekker NP, Lozada-Nur F, Lagenaur LA, MacPhail LA, Bloom CY, Regezi JA. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1997; 26: 170-5.
28. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000; 29: 413-25.
29. Schifter M, Jones AM, Walker DM. Epithelial p53 gene expression and mutational analysis, combined with growth fraction assessment, in oral lichen planus. J Oral Pathol Med 1998; 27: 318-24.
30. Girod SC, Pfeiffer P, Ries J, Pape HD. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1998; 36: 252-60.
31. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer 2000; 87: 368-72.
32. Tanda N, Mori S, Saito K, Ikawa K, Sakamoto S. Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies. J Oral Pathol Med 2000; 29: 385-93.
33. Valente G, Pagano M, Carrozzo M, et al. Sequential immunohistochemical p53 expression in biopsies of oral lichen planus undergoing malignant evolution. J Oral Pathol Med 2001; 30: 135-40.
34. Hirota M, Ito T, Okudela K, et al. Cell proliferation activity and the expression of cell cycle regulatory proteins in oral lichen planus. J Oral Pathol Med 2002; 31: 204-12.
35. Ogmundsdottir HM, Hilmarsdottir H, Astvaldsdottir A, Johannsson JH, Holbrook WP. Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in Icelande. Eur J Oral Sci 2002; 110: 192-8.
36. Taniguchi Y, Nagao T, Maeda H, Kameyama Y, Warnakulasuriya KA. Epithelial cell proliferation in oral lichen planus. Cell Prolif 2002; 35: 103-9.
37. Chaiyarit P, Ma N, Hiraku Y, et al. Nitrative and oxidative DNA damage in oral lichen planus in relation to human oral carcinogenesis. Cancer Sci 2005; 96: 553-9.
38. Acay RR, Felizzola CR, de Araújo N, de Sousa SO. Evaluation of proliferative potential in oral lichen planus and oral licheoid lesions using immunohistochemical expression of p53 and Ki67. Oral Oncol 2006; 42: 475-80.
39. Ebrahimi M, Wahlin YB, Coates PJ, Sjöström B, Nylander K. Decreased expression of p63 in oral lichen planus and graft-vs.-host disease associated with oral inflammation. J Oral Pathol Med 2006; 35: 46-50.
40. González-Moles MA, Bascones-Ilundain C, Gil Montoya JA, Ruiz-Avila I, Delgado-Rodríguez M, Bascones-Martínez A. Cell cycle regulating mechanisms in oral lichen planus: molecular bases in epithelium predisposed to malignant transformation. Arch Oral Biol 2006; 51: 1093-103.
41. González-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Bascones-Martinez A. Differences in the expression of p53 protein in oral lichen planus based on the use of monoclonal antibodies DO7 and pAb 240. Oral Oncol 2008; 44: 496-503.
42. Sousa FA, Paradella TC, Carvalho YR, Rosa LE. Immunohistochemical expression of PCNA, p53, bax and bcl-2 in oral lichen planus and epithelial dysplasia. J Oral Sci 2009; 51: 117-21.
43. Safadi RA, Al Jaber SZ, Hammad HM, Hamasha AA. Oral lichen planus shows higher expressions of tumor suppressor gene products of p53 and p21 compared to oral mucositis. An immunohistochemical study. Arch Oral Biol 2010; 55: 454-61.
44. McCluggage WG, Connolly LE, McGregor G, Hyland PL, Hall PA. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 2005; 24: 307-12.
45. Ebrahimi M, Boldrup L, Wahlin YB, Coates PJ, Nylander K. Expression of novel p53 isoforms in oral lichen planus. Oral Oncol 2008; 44: 156-61.
46. Boldrup L, Bourdon JC, Coates PJ, Sjöström B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007; 43: 617-23.
47. Sniezek JC, Matheny KE, Burkey BB, Netterville JL, Pietenpol JA. Expression of p63 and 14-3-3sigma in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngol Head Neck Surg 2002; 126: 598-601.
48. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004; 114: 2063-72.
49. Lee LA, Walsh P, Prater CA, et al. Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. J Invest Dermatol 1999; 113: 146-51.
50. Ebrahimi M, Nylander E, Bäcklund B, Wahlin YB, Coates PJ, Nylander K. The use of a novel ELISA method for detection of antibodies against p63 in sera from patients diagnosed with oral and/or genital and skin lichen planus. J Oral Pathol Med 2010; 6: 486-90.
51. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
52. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 2004; 40: 120-30.
53. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
54. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV- irradiated normal human skin. Oncogene 1993; 8: 203-7.
55. Hall PA, Campbell SJ, O'Neill M, et al. The expression of the p53 homologue, p63a and DNp63a in normal and neoplastic cells. Carcinogenesis 2000; 21: 153-60.
56. Hildesheim J, Belova GI, Tyner SD, Zhou X, Vardanian L, Fornace AJ Jr. Gadd45a regulates matrix metalloproteinases by suppressing DeltaNp63alpha and beta-catenin via p38 MAP kinase and APC complex activation. Oncogene 2004; 23: 1829-37.
57. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60: 4016-20.
58. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-8.